...ob ihr (wir) wirklich richtig steht, seht ihr erst, wenn das Licht angeht. Bin immernoch von dem Konzept überzeugt, für einen "Zock" finde ich CBAI ungeeignet und eine ernsthafte Chartanalsye ist hier wohl auch nicht durchführbar.
Dein Wort in Gottes Ohr.Ich stehe zwar auch hinter diesem Konzept,aber ich traue den Amis nicht über den Weg.Das sind weltweit die größten Betrüger die es nur gibt. Sie können rein garnichts von alleine.Ich hoffe die ersticken an ihre Schulden.Wie kann man eigentlich überhaupt so leben.Wer über seine Verhältnisse über Jahrzehnte lebt ,muss irgendwann auch die Zeche bezahlen.Wir als Europäer kriechen den noch in den Arsch ,angefangen von Merkel,bei der man den Kopf schon nicht mal mehr sieht.
: Cord Blood America (OTC BB: CBAI): In The News
Cord Blood America (OTC BB: CBAI) is the stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally. This clipping service will keep you up-to-date on accomplishments in this important health arena.
Researchers to study baby blindness Tuesday, 17 May 2011 Belfast Telegraph New research in Northern Ireland could help tackle an illness causing blindness in premature babies.
Scientists at Queen's University Belfast are teaming up to develop a cure for the condition thanks to funding from children's charity Action Medical Research.
Two teams from the Centre for Vision and Vascular Science are taking different approaches to a condition called retinopathy of prematurity (ROP).
ROP is caused by blood vessels in the eye growing abnormally and causing damage to the retina - the light-sensitive inner lining of the eye.The condition can lead to blindness in premature babies, putting the youngest, sickest and smallest babies most at risk.
Derek Brazil is to lead a team investigating whether stem cells from babies' own umbilical cords might have the power to repair their damaged eyes.
He said: "We hope our laboratory work will reveal whether vascular stem cells have the potential to repair damage to babies' eyes and save their sight. If so, it is possible that in the future vascular stem cells could be taken from a baby's own umbilical cord just after birth and then grown in the laboratory in case treatment is needed."
Taking a different approach, a team led by Denise McDonald is exploring a key step in the early stages of the disease process.
While laser treatment tackles stage two of the disease process, by stopping abnormal blood vessels from growing, by this stage the disease can already be quite severe.
Dr McDonald and her team are looking for possible new treatments which will protect the retinal blood vessels from the effect of high oxygen which occurs in stage one.
Alexandra Dedman of Action Medical Research said: "We are delighted to be funding these two expert research teams in Belfast who both have long-standing track records, recognised internationally. Their work in this area has the potential to change the lives of babies around the world suffering from this condition."
***** GIRL WITH CEREBRAL PALSY TREATED WITH OWN CORD BLOOD STEM CELLS Reuters July 28, 2011
Ground breaking medical treatment Medical doctors at Duke University are treating cerebral palsy patients who have their own cord blood stored, in a clinical trial. In a simple and safe procedure, the stem cells from umbilical cord blood that were stored at birth are transfused back into the children, in what is called an autologous stem cell transfusion (using one's own stem cells).
Parents have noticed significant improvements in their children who suffer from cerebral palsy after receiving their own cord blood transfusion and this and other similar trials around the world hope to show conclusive evidence.
Study: Umbilical Cord Mesenchymal Stem Cells Infusion in Cirrhosis Patients Clinical Trials Govt. July 26, 2011 Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients. The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis.
To investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis. Patients with liver cirrhosis were randomly separated into two groups. Umbilical cord MSCs were infused to patients using interventional method via hepatic artery for One group. After the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord MSCs were infused slowly for 15-20minutes. The control group accepted conserved therapy.
Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes. Intervention: Biological: umbilical cord Mesenchymal Stem Cells ClinicalTrials.gov
The Celle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com
: Ich hoffe hier passiert mal endlich was .
LAS VEGAS, Aug. 29, 2011 /PRNewswire/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI) announced today it has entered into an agreement with BancoVida (www.bancovida.com) to offer umbilical cord blood collection services in Puerto Rico and throughout the Caribbean.
The partnership will allow BancoVida and Cord Blood America to educate prospective parents in Puerto Rico and the Caribbean on the value of storing their baby's umbilical cord blood. The stem cells will be stored at Cord Blood America's state-of-the-art facility in Las Vegas.
"We are very excited about our partnership with BancoVida and for the opportunity to assist them in bringing this potentially life-saving service to an underserved area," said Gabby Stinson, Cord Blood America Project Manager.
Cord blood stem cells, which are collected at birth in a non-invasive procedure, are currently used to treat more than 70 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. Various studies and clinical trials are currently underway to determine the effectiveness of stem cells in treating some of the most serious diseases, such as diabetes, heart disease, Parkinson's and cerebral palsy for which there is no known cure.
BancoVida Corp. has been established to develop and market private cord blood banking services to patients in Puerto Rico and the Caribbean. Our mission is to successfully introduce and become the leader of private cord blood banking in the Caribbean. BancoVida is the exclusive reseller of cord blood banking services for Cord Blood America and CorCell in Puerto Rico and the Caribbean. To find out more about BancoVida, visit our website at www.bancovida.com.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI.ob) is the parent company of CorCell Companies, Inc., which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
: New Service for South American Storage Company:
Storing Bone Marrow Stem Cells Prior to Cancer Surgeries
LAS VEGAS, Aug. 31, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Biocordcell Argentina S.A., headquartered in Buenos Aires, its stem cell storage company which services South America and Miami, Florida, has begun storing bone marrow stem cells prior to transplantation in treatments for cancer.
"The storage is short term, for three months or less, and it is done at a hospital in Buenos Aires," said Diego Rissola, President of BioCells Argentina. "It is important since it diversifies our revenue stream, contributes to the fight against cancer, and emphasizes the quality and reputation of our storage company."
"We are pleased to see our international companies be aggressive in increasing revenues and in utilizing new ideas to promote gross profits," said Matthew Schissler, Cord Blood America CEO and co-founder. "Diversification of revenues has been one of our three pillars of success for the last two years. In that time CBAI''s group of companies have launched placental stem cell collection services, whole umbilical cord tissue collection services, dental pulp stem cell storage services, and now bone marrow stem cell storage services. These services have partly contributed to our increase in revenues, as reported in our last two Form 10Q filings with the United States Securities and Exchange Commission, including the 61% year over year revenue increase reported for second quarter 2011."
So langsam kommt mir bei der Drecksaktie das kotzen. Wo ist eigentlich dieser Drecksack von Schissler,oder hat der sich schon mit unserer Kohle aus dem Staub gemacht.Scheiß Amidreckspack ,alles nur Heuchler und Betrüger.Für mich ist das Thema Amiaktien erledigt.